Risk Reduction or Treat-To-Target Strategy? Economic Assessment of Statin use in Cardiovascular Prevention

      The latest ACC/AHA guidelines on high blood cholesterol management have raised controversy regarding especially the elimination of the LDL-C treat-to-target strategy and the adoption of a fixed-dose statin risk reduction strategy. Opponents argue that it could induce confusion among professionals, decrease in follow-up and patient adherence. We compared benefits and costs of applying the 2013 ACC/AHA Guidelines, ‘fixed-dose strategy’, and the 2016 ESC/EAS Guidelines, ‘target strategy’.
      To read this article in full you will need to make a payment
      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect